Sign up
Pharma Capital

Scancell recruits deal maker to take over as CEO

Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes
Cancer therapeutics
Dr Holloway's expertise in cancer therapeutics will be invaluable to Scancell

Scancell Holdings PLC (LON:SCLP) has nabbed Dr Cliff Holloway from Benitec Biopharma to be its new chief executive officer, succeeding Dr Richard Goodfellow.

Goodfellow will remain on the board of directors.

READ: Scancell on the lookout for partners after year of “significant progress”

Holloway will seek to drive progress of Scancell's immunotherapy platforms ImmunoBody and Moditope and oversee their commercialisation, the company said.

Holloway was previously chief business and operating officer at Benitec, and before that was chief executive officer of Sienna Cancer Diagnostics.

John Chiplin, executive chairman of Scancell, paid tribute to Goodfellow, saying if it wasn't for his significant achievements, Scancell would not be in the position it's in today.

“We are about to embark on a Phase 2 checkpoint inhibitor combination study with our ImmunoBody vaccine, SCIB1, in melanoma; and our lead Moditope, Modi-1, is progressing rapidly towards the clinic. I would like to thank Richard wholeheartedly for his hard work and substantial contribution to the business, and look forward to continue working alongside him on the board of directors,” Chiplin said.

READ: Scancell presents Moditope data at prestigious cancer conference

Dr Goodfellow said the appointment of Dr Holloway would ensure that Scancell has “a leader with the right mix of skills to guide the company into its next phase of growth”.

“Cliff is an experienced deal maker, which combined with his deep understanding of the science makes him an ideal choice for the job. I have known Cliff for over 10 years and very much look forward to supporting him in his new position," Dr Goodfellow said.

Shares in Scancell were down 1.1% at 12.36p in early deals.

John-H.jpg
Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile

Scancell Holdings Plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.